Abbott Laboratories (ABT.N)
68.50USD
19 Sep 2018
$0.09 (+0.13%)
$68.41
$68.52
$68.96
$68.40
1,048,762
1,454,511
$68.96
$51.37
About
Overall
| Beta: | 1.57 |
| Market Cap(Mil.): | $95,559.38 |
| Shares Outstanding(Mil.): | 1,737.44 |
| Dividend: | 0.26 |
| Yield (%): | 1.93 |
Financials
| ABT.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 84.45 | 30.93 | 32.76 |
| EPS (TTM): | 0.65 | -- | -- |
| ROI: | 2.24 | 15.07 | 14.61 |
| ROE: | 4.07 | 16.59 | 16.33 |
Abbott Labs raises 2018 earnings forecast, shares hit record high
Abbott Laboratories raised its full-year earnings forecast and topped estimates for quarterly profit on Wednesday, powered by demand for its glucose monitoring device for diabetics and gains from its multibillion dollar acquisitions.
UPDATE 2-Abbott Labs raises 2018 earnings forecast, shares hit record high
* Shares hit record high (Adds details from conference call, analysts' quotes, updates shares)
Abbott Labs tops profit estimates, raises full-year earnings forecast
July 18 Abbott Laboratories raised its full-year earnings forecast and reported a quarterly profit that beat analysts' estimates, powered by higher sales across its businesses, including its top-earning medical device unit.
Allergan appoints former Abbott executive to its board
Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.
Allergan appoints former Abbott executive to its board
June 14 Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.
BRIEF-Abbott Expands Cardiac Arrhythmias Portfolio With FDA Clearance Of Advanced Mapping Catheter
* ABBOTT EXPANDS CARDIAC ARRHYTHMIAS PORTFOLIO WITH FDA CLEARANCE OF ADVANCED MAPPING CATHETER
Outgoing Smith & Nephew CEO signs off with a downgrade
LONDON Smith & Nephew downgraded its revenue and profit forecasts after a weak first quarter on Thursday, days before Chief Executive Olivier Bohuon will end his seven-year tenure at the artificial knee and hip maker.
UPDATE 2-Outgoing Smith & Nephew CEO signs off with a downgrade
* Shares fall 7 pct (Adds CEO comments, analyst reaction, shares)
BRIEF-Abbott's Xience Sierra Heart Stent Receives National Reimbursement In Japan
* ABBOTT'S XIENCE SIERRA™ HEART STENT RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PEOPLE WITH CORONARY ARTERY DISEASE Source text for Eikon: Further company coverage:
BRIEF-Abbott Laboratories Says Shareholders Rejected Proposal Requesting Board Of Directors Adopt Policy That Board Chairman Be Independent Director
* ABBOTT LABORATORIES SAYS SHAREHOLDERS REJECTED PROPOSAL REQUESTING CO'S BOARD OF DIRECTORS ADOPT POLICY THAT BOARD CHAIRMAN BE INDEPENDENT DIRECTOR Source text: (https://bit.ly/2KqCwQY) Further company coverage:
Competitors
| Price | Chg | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $140.46 | -0.08 |
| Pfizer Inc. (PFE.N) | $43.26 | -0.25 |
| Novartis AG (NOVN.S) | CHF81.74 | +0.28 |
| Merck & Co., Inc. (MRK.N) | $69.98 | -0.44 |
| Sanofi SA (SASY.PA) | €75.12 | +0.22 |
| AstraZeneca plc (AZN.L) | 5,601.00 | -8.00 |
| GlaxoSmithKline plc (GSK.L) | 1,496.80 | +10.00 |
| Eli Lilly And Co (LLY.N) | $105.74 | -1.14 |
| Amgen, Inc. (AMGN.OQ) | $203.20 | +0.86 |
| Boston Scientific Corporation (BSX.N) | $37.49 | -0.13 |
Estimates